safe skin practices, including sun avoidance and SSE. Safe skin practices are as important as regular exercise and smoking cessation and should be included in routine health education counseling.
1. Hu S, Parmet Y, Allen G, et al. Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among whites, Hispanics, and blacks in Florida. Arch Dermatol. 2009; 145(12) 
Quality of Life Differences Between Responders and Nonresponders in the Treatment of Cutaneous Lupus Erythematosus
P atients with cutaneous lupus erythematosus (CLE) have very poor quality of life. 1 When compared with those with other skin diseases, patients with CLE are among those most severely affected by their condition. Psychologic aspects of quality of life in CLE are similar to, or worse than, what is experienced by patients with chronic hypertension, congestive heart failure, type 2 diabetes mellitus, and recent myocardial infarction. In considering this, we were interested in assessing whether patients who demonstrated response to treatment also experienced change to their quality of life.
Methods. This institutional review board-approved study prospectively evaluated response to systemic therapy in patients with CLE using the CLE Disease Area and Severity Index (CLASI) 2 and the Skindex-29. 3 The CLASI is a validated clinical tool that quantifies disease activity and damage separately, with higher scores indicating more severe disease. The Skindex-29 is a validated, skinspecific quality of life measure that calculates 3 subscale scores: Emotions, Functioning, and Symptoms, with higher scores indicating worse quality of life. Eligible patients met modified Gilliam criteria 4 for CLE and had at least 2 visits during which CLASI and Skindex-29 scores were measured. Patients with a diagnosis of systemic lupus erythematosus (SLE) were included. Details regarding the identification of eligible patients have been discussed previously.
5 From among the eligible patients, those who had been initiated on antimalarial therapy (hydroxychloroquine, hydroxychloroquinequinacrine, chloroquine, or chloroquine-quinacrine) or antimetabolite therapy (methotrexate, mycophenolate, or azathioprine) were identified. Twenty-seven patients were initiated on antimalarial therapy. Hydroxychloroquine was dosed at 200 to 400 mg/d, and chloroquine was dosed at 250 mg/d for 5 to 7 days per week, based on ideal body weight. Quinacrine was dosed at 100 mg/d. Twelve patients were initiated on antimetabolite therapy. Antimetabolite treatment was initiated at a low dose, and the dose was increased until the lowest effective and tolerated dose was achieved. The median (interquartile range [IQR]) dose for methotrexate was 13.8 (10.6-16.3) mg/ wk; for mycophenolate, it was 2000 (1750-2500) mg/d; for azathioprine, 100 (75-125) mg/d. For 6 of 39 patients included in this study, data were available for initiation of two systemic therapies. In these cases, data from the first therapy that was initiated were included, and the remainder were excluded.
Consistent with previous work, 5,6 response was defined as either a 4-point or 20% decrease in CLASI activity score and determined by comparing the score at the pretreatment visit with the first posttreatment visit. The first posttreatment visit occurred at least 2 months following the pretreatment visit. For patients with more Carly Roman Aída Lugo-Somolinos, MD Nancy Thomas, MD, PhD than 1 posttreatment visit, the first posttreatment visit was used. All responders and nonresponders were pooled together, regardless of which systemic therapy was initiated, and Skindex-29 subscale scores were compared between the pretreatment visit and the first posttreatment visit.
Skindex-29 subscale scores were normally distributed, and paired t tests were used. Spearman correlation tests were performed between change in Skindex-29 subscale score and change in CLASI activity score. Stata software, version 11.0 (StataCorp LP) and GraphPad Prism, version 5.0 (GraphPad Software Inc) were used for data analysis.
Results. For 23 responders of 39 patients initiated on an antimalarial or antimetabolite therapy, the mean (95% CI) Emotions score decreased from 53.9 (40.6-67.1) to 38.8 (28.2-49.4) (P = .002); Functioning score decreased from 32.7 (20.5-44.9) to 20.9 (13.1-28.7) (P=.01); and Symptoms score decreased from 47.2 (37.8-56.6) to 33.7 (26.6-40.8) (PϽ.001) (Figure, A) . For the 16 nonresponders, the mean (95% CI) Emotions, Functioning, and Symptoms scores were unchanged: 48.0 (33.3-62.7) to 53.0 (38.3-67.6) (P = .30); 25.1 (13.2-37.1) to 25.1 (13.2-37.1) (P Ͼ.99); and 44.2 (32.4-56.0) to 43.0 (28.1-57.8) (P = .81), respectively (Figure, B) . Differences in pretreatment CLASI scores, duration between visits, diagnosis (CLE only vs CLE and SLE), age, sex, and smoking status between responders and nonresponders were not statistically significant. Change in CLASI activity score was correlated with change in Skindex-29 subscale scores: Emotions, r=0.39 (P=.01); Functioning, r=0.29 (P=.07); and Symptoms, r=0.33 (P=.04).
Comment. Response in disease activity was accompanied by an improvement in skin-specific quality of life measures. Correlation analysis suggests that disease activity is not the only factor influencing quality of life. The impact of treatment adverse effects on quality of life is unaccounted for in this study because various medications were used. Larger studies of systemic therapies in CLE that focus on quality of life and its contributory factors are needed. 
Mortality of Bullous Pemphigoid in China

B
ullous pemphigoid (BP) is the most common acquired autoimmune blistering disorder that occurs mostly in elderly people. The first-year mortality has been reported to range from 6% to 41%. [1] [2] [3] This study determined the 1-, 2-, and 5-year mortality of patients with BP in China and identified risk factors affecting survival. The mortality of patients with BP was compared with age-matched persons in the general population.
Methods. This was a retrospective cohort study. Inclusion criteria were a diagnosis of BP based on clinical characteristics and confirmed by at least a typical histologic pattern and the presence of autoantibodies against the basement membrane zone detected by direct and/or indirect immunofluorescence testing. The treatment for BP was oral corticosteroids with or without adjuvant therapy such as dapsone, cyclophosphamide, and others. Data were obtained of all patients with a discharge diagnosis of BP between January 1991 and 2011. Information on the status of patients who became unavailable for follow-up by the hospital department was obtained by telephone calls.
The mortality at 1, 2, and 5 years after first hospitalization was calculated based on the Kaplan-Meier survival estimate. Cox logistic regression in multivariate analysis was used. For the analysis, if no predefined cutoff points were available, continuous variables were categorized on the basis of the median. The ratio of the observed to expected death rates, or the standardized mortality ratio (SMR), was calculated for age categories. The study was approved by the ethics committee of Peking Union Medical College.
Results. A total of 140 patients with BP and a follow-up time 1 year or longer were included. The median age was 67 years, and the mean (SD) age was 64.3 (13.6) years (age range, 18-93 years). The median time from onset of disease to hospitalization was 2.94 months (range, 7 days to 30 years). The median follow-up time was 3 years. The 1-year mortality was 12.9% (95% CI, 8.3%-19.6%); the 2-year mortality was 20.1% (95% CI, 14.4%-28.0%); and the 5-year mortality was 33.5% (95% CI, 25.6%-43.1%) (Figure) .
In the univariate analysis, several variables increased mortality ( Table 1) . Nonsignificant comparisons included smokers vs never smokers (P=.20), drinkers vs never drinkers (P = .33), urban vs rural population (P=.06), duration of disease longer than 2.94 months vs 2.94 months or shorter (P =.25), and erythrocyte sedimentation rate higher than 23 mm/h vs 23 mm/h or less.
The SMR varied from 3.08 to 6.14 depending on age group ( Table 2) . Based on these data, we concluded that the mortality of patients in our BP cohort was higher than would be expected in age-matched persons in the general Chinese population.
Comment. In our study, the 1-year mortality was 12.9%, which is similar to rates reported in previously pub- 
